PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients and Clinical Samples
2.2. Cell Culture and Cytospin Preparation
2.3. Isolation of CTCs
2.4. Immunofluorescence and Confocal Imaging
2.5. Statistical Analysis
3. Results
3.1. Detection of CTCs in NSCLC Patients
3.2. Detection of PD-L1+ CTCs in NSCLC Patients and Identification of Different Phenotypes
3.3. Detection of pS6+ CTCs in NSCLC Patients and Identification of Different Phenotypes
3.4. Correlation between PD-L1 and pS6 Expression in NSCLC Patients’ CTCs
3.5. Clinical Outcome Based on the Presence of PD-L1+ and pS6+ CTCs
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
References
- Pantazaka, E.; Vardas, V.; Roumeliotou, A.; Kakavogiannis, S.; Kallergi, G. Clinical relevance of mesenchymal- and stem-associated phenotypes in circulating tumor cells isolated from lung cancer patients. Cancers 2021, 13, 2158. [Google Scholar] [CrossRef] [PubMed]
- Qian, H.; Zhang, Y.; Xu, J.; He, J.; Gao, W. Progress and application of circulating tumor cells in non-small cell lung cancer. Mol. Ther. Oncolytics 2021, 22, 72–84. [Google Scholar] [CrossRef] [PubMed]
- Koh, Y.; Yagi, S.; Akamatsu, H.; Kanai, K.; Hayata, A.; Tokudome, N.; Akamatsu, K.; Higuchi, M.; Kanbara, H.; Nakanishi, M.; et al. Heterogeneous expression of programmed death receptor-ligand 1 on circulating tumor cells in patients with lung cancer. Clin. Lung Cancer 2019, 20, 270–277.e271. [Google Scholar] [CrossRef] [Green Version]
- Gallo, M.; De Luca, A.; Maiello, M.R.; D’Alessio, A.; Esposito, C.; Chicchinelli, N.; Forgione, L.; Piccirillo, M.C.; Rocco, G.; Morabito, A.; et al. Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. Transl. Lung Cancer Res. 2017, 6, 486–498. [Google Scholar] [CrossRef] [Green Version]
- Kallergi, G.; Kontopodis, E.; Ntzifa, A.; Jordana-Ariza, N.; Karachaliou, N.; Pantazaka, E.; Charalambous, H.A.; Psyrri, A.; Tsaroucha, E.; Boukovinas, I.; et al. Effect of osimertinib on CTCs and ctDNA in EGFR mutant non-small cell lung cancer patients: The prognostic relevance of liquid biopsy. Cancers 2022, 14, 1574. [Google Scholar] [CrossRef] [PubMed]
- Ramalingam, S.S.; Vansteenkiste, J.; Planchard, D.; Cho, B.C.; Gray, J.E.; Ohe, Y.; Zhou, C.; Reungwetwattana, T.; Cheng, Y.; Chewaskulyong, B.; et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 2020, 382, 41–50. [Google Scholar] [CrossRef]
- Hsu, W.H.; Yang, J.C.; Mok, T.S.; Loong, H.H. Overview of current systemic management of EGFR-mutant NSCLC. Ann. Oncol. 2018, 29, i3–i9. [Google Scholar] [CrossRef]
- Harrison, P.T.; Vyse, S.; Huang, P.H. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin. Cancer Biol. 2020, 61, 167–179. [Google Scholar] [CrossRef]
- Janne, P.A.; Yang, J.C.; Kim, D.W.; Planchard, D.; Ohe, Y.; Ramalingam, S.S.; Ahn, M.J.; Kim, S.W.; Su, W.C.; Horn, L.; et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015, 372, 1689–1699. [Google Scholar] [CrossRef]
- Acheampong, E.; Spencer, I.; Lin, W.; Ziman, M.; Millward, M.; Gray, E. Is the blood an alternative for programmed cell death ligand 1 assessment in non-small cell lung cancer? Cancers 2019, 11, 920. [Google Scholar] [CrossRef] [Green Version]
- Papadaki, M.A.; Sotiriou, A.I.; Vasilopoulou, C.; Filika, M.; Aggouraki, D.; Tsoulfas, P.G.; Apostolopoulou, C.A.; Rounis, K.; Mavroudis, D.; Agelaki, S. Optimization of the enrichment of circulating tumor cells for downstream phenotypic analysis in patients with non-small cell lung cancer treated with anti-PD-1 immunotherapy. Cancers 2020, 12, 1556. [Google Scholar] [CrossRef] [PubMed]
- Mondelo-Macia, P.; Garcia-Gonzalez, J.; Leon-Mateos, L.; Anido, U.; Aguin, S.; Abdulkader, I.; Sanchez-Ares, M.; Abalo, A.; Rodriguez-Casanova, A.; Diaz-Lagares, A.; et al. Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab. Mol. Oncol. 2021, 15, 2923–2940. [Google Scholar] [CrossRef] [PubMed]
- Janning, M.; Kobus, F.; Babayan, A.; Wikman, H.; Velthaus, J.L.; Bergmann, S.; Schatz, S.; Falk, M.; Berger, L.A.; Bottcher, L.M.; et al. Determination of PD-L1 expression in circulating tumor cells of NSCLC patients and correlation with response to PD-1/PD-L1 inhibitors. Cancers 2019, 11, 835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kulasinghe, A.; Kapeleris, J.; Cooper, C.; Warkiani, M.E.; O’Byrne, K.; Punyadeera, C. Phenotypic characterization of circulating lung cancer cells for clinically actionable targets. Cancers 2019, 11, 380. [Google Scholar] [CrossRef] [Green Version]
- Dhar, M.; Wong, J.; Che, J.; Matsumoto, M.; Grogan, T.; Elashoff, D.; Garon, E.B.; Goldman, J.W.; Sollier Christen, E.; Di Carlo, D.; et al. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci. Rep. 2018, 8, 2592. [Google Scholar] [CrossRef] [PubMed]
- Cheng, Y.; Wang, T.; Lv, X.; Li, R.; Yuan, L.; Shen, J.; Li, Y.; Yan, T.; Liu, B.; Wang, L. Detection of PD-L1 expression and its clinical significance in circulating tumor cells from patients with non-small-cell lung cancer. Cancer Manag. Res. 2020, 12, 2069–2078. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ilie, M.; Szafer-Glusman, E.; Hofman, V.; Chamorey, E.; Lalvee, S.; Selva, E.; Leroy, S.; Marquette, C.H.; Kowanetz, M.; Hedge, P.; et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann. Oncol. 2018, 29, 193–199. [Google Scholar] [CrossRef]
- Kallergi, G.; Vetsika, E.K.; Aggouraki, D.; Lagoudaki, E.; Koutsopoulos, A.; Koinis, F.; Katsarlinos, P.; Trypaki, M.; Messaritakis, I.; Stournaras, C.; et al. Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. Ther. Adv. Med. Oncol. 2018, 10, 1758834017750121. [Google Scholar] [CrossRef]
- Ntzifa, A.; Strati, A.; Kallergi, G.; Kotsakis, A.; Georgoulias, V.; Lianidou, E. Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. Sci. Rep. 2021, 11, 2313. [Google Scholar] [CrossRef]
- Sun, S.Y. Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Transl. Oncol. 2020, 13, 100847. [Google Scholar] [CrossRef]
- Krencz, I.; Sebestyen, A.; Papay, J.; Jeney, A.; Hujber, Z.; Burger, C.D.; Keller, C.A.; Khoor, A. In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human lymphangioleiomyomatosis. Hum. Pathol. 2018, 79, 199–207. [Google Scholar] [CrossRef] [PubMed]
- Ruvinsky, I.; Meyuhas, O. Ribosomal protein S6 phosphorylation: From protein synthesis to cell size. Trends Biochem. Sci. 2006, 31, 342–348. [Google Scholar] [CrossRef] [PubMed]
- Chen, B.; Zhang, W.; Gao, J.; Chen, H.; Jiang, L.; Liu, D.; Cao, Y.; Zhao, S.; Qiu, Z.; Zeng, J.; et al. Downregulation of ribosomal protein S6 inhibits the growth of non-small cell lung cancer by inducing cell cycle arrest, rather than apoptosis. Cancer Lett. 2014, 354, 378–389. [Google Scholar] [CrossRef]
- McDonald, J.M.; Pelloski, C.E.; Ledoux, A.; Sun, M.; Raso, G.; Komaki, R.; Wistuba, I.I.; Bekele, B.N.; Aldape, K. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin. Cancer Res. 2008, 14, 7832–7837. [Google Scholar] [CrossRef] [Green Version]
- Lastwika, K.J.; Wilson, W., 3rd; Li, Q.K.; Norris, J.; Xu, H.; Ghazarian, S.R.; Kitagawa, H.; Kawabata, S.; Taube, J.M.; Yao, S.; et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016, 76, 227–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Woo, S.U.; Sangai, T.; Akcakanat, A.; Chen, H.; Wei, C.; Meric-Bernstam, F. Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. Oncogenesis 2017, 6, e385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Romero-Pozuelo, J.; Figlia, G.; Kaya, O.; Martin-Villalba, A.; Teleman, A.A. Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1. Cell Rep. 2020, 31, 107504. [Google Scholar] [CrossRef]
- Meng, S.; Tripathy, D.; Frenkel, E.P.; Shete, S.; Naftalis, E.Z.; Huth, J.F.; Beitsch, P.D.; Leitch, M.; Hoover, S.; Euhus, D.; et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 2004, 10, 8152–8162. [Google Scholar] [CrossRef] [Green Version]
- Gyorffy, B.; Surowiak, P.; Budczies, J.; Lanczky, A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE 2013, 8, e82241. [Google Scholar] [CrossRef] [Green Version]
- Sinoquet, L.; Jacot, W.; Gauthier, L.; Pouderoux, S.; Viala, M.; Cayrefourcq, L.; Quantin, X.; Alix-Panabieres, C. Programmed cell death ligand 1-expressing circulating tumor cells: A new prognostic biomarker in non-small cell lung cancer. Clin. Chem. 2021, 67, 1503–1512. [Google Scholar] [CrossRef]
- Lianidou, E.S.; Markou, A.; Strati, A. The role of CTCs as tumor biomarkers. Adv. Exp. Med. Biol. 2015, 867, 341–367. [Google Scholar] [CrossRef] [PubMed]
- Guibert, N.; Delaunay, M.; Lusque, A.; Boubekeur, N.; Rouquette, I.; Clermont, E.; Mourlanette, J.; Gouin, S.; Dormoy, I.; Favre, G.; et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer 2018, 120, 108–112. [Google Scholar] [CrossRef] [PubMed]
- Tamminga, M.; de Wit, S.; Hiltermann, T.J.N.; Timens, W.; Schuuring, E.; Terstappen, L.; Groen, H.J.M. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. J. Immunother. Cancer 2019, 7, 173. [Google Scholar] [CrossRef] [PubMed]
- Dall’Olio, F.G.; Gelsomino, F.; Conci, N.; Marcolin, L.; De Giglio, A.; Grilli, G.; Sperandi, F.; Fontana, F.; Terracciano, M.; Fragomeno, B.; et al. PD-L1 expression in circulating tumor cells as a promising prognostic biomarker in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Clin. Lung Cancer 2021, 22, 423–431. [Google Scholar] [CrossRef]
- Dong, J.; Zhu, D.; Tang, X.; Qiu, X.; Lu, D.; Li, B.; Lin, D.; Zhou, Q. Detection of circulating tumor cell molecular subtype in pulmonary vein predicting prognosis of stage I-III non-small cell lung cancer patients. Front. Oncol. 2019, 9, 1139. [Google Scholar] [CrossRef]
- Chen, Y.L.; Huang, W.C.; Lin, F.M.; Hsieh, H.B.; Hsieh, C.H.; Hsieh, R.K.; Chen, K.W.; Yen, M.H.; Lee, J.; Su, S.; et al. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naive, newly diagnosed patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2019, 68, 1087–1094. [Google Scholar] [CrossRef] [Green Version]
- Nicolazzo, C.; Raimondi, C.; Mancini, M.; Caponnetto, S.; Gradilone, A.; Gandini, O.; Mastromartino, M.; Del Bene, G.; Prete, A.; Longo, F.; et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci. Rep. 2016, 6, 31726. [Google Scholar] [CrossRef]
- Wang, H.L.; Wu, J.Q.; Wang, Y.; Yu, J.; Mao, X.N.; Li, Z.R.; Niu, H.R.; Jin, C.L.; Wang, X.J.; Yan, Z.H.; et al. Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer. Neoplasma 2021, 68, 823–831. [Google Scholar] [CrossRef]
- Manjunath, Y.; Upparahalli, S.V.; Avella, D.M.; Deroche, C.B.; Kimchi, E.T.; Staveley-O’Carroll, K.F.; Smith, C.J.; Li, G.; Kaifi, J.T. PD-L1 expression with epithelial mesenchymal transition of circulating tumor cells is associated with poor survival in curatively resected non-small cell lung cancer. Cancers 2019, 11, 806. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Kim, T.H.; Fouladdel, S.; Zhang, Z.; Soni, P.; Qin, A.; Zhao, L.; Azizi, E.; Lawrence, T.S.; Ramnath, N.; et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci. Rep. 2019, 9, 566. [Google Scholar] [CrossRef] [Green Version]
- Ikeda, M.; Koh, Y.; Teraoka, S.; Sato, K.; Oyanagi, J.; Hayata, A.; Tokudome, N.; Akamatsu, H.; Ozawa, Y.; Endo, K.; et al. Longitudinal evaluation of PD-L1 expression on circulating tumor cells in non-small cell lung cancer patients treated with nivolumab. Cancers 2021, 13, 2290. [Google Scholar] [CrossRef] [PubMed]
- Boffa, D.J.; Graf, R.P.; Salazar, M.C.; Hoag, J.; Lu, D.; Krupa, R.; Louw, J.; Dugan, L.; Wang, Y.; Landers, M.; et al. Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival. Cancer Epidemiol. Biomark. Prev. 2017, 26, 1139–1145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adams, D.L.; Adams, D.K.; He, J.; Kalhor, N.; Zhang, M.; Xu, T.; Gao, H.; Reuben, J.M.; Qiao, Y.; Komaki, R.; et al. Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy. Clin. Cancer Res. 2017, 23, 5948–5958. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ouyang, Y.; Liu, W.; Zhang, N.; Yang, X.; Li, J.; Long, S. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis. Cancer Med. 2021, 10, 7021–7039. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Lian, Z.; Wang, S.; Xing, L.; Yu, J. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. Cancer Lett. 2018, 418, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Deng, L.; Qian, G.; Zhang, S.; Zheng, H.; Fan, S.; Lesinski, G.B.; Owonikoko, T.K.; Ramalingam, S.S.; Sun, S.Y. Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation. Oncogene 2019, 38, 6270–6282. [Google Scholar] [CrossRef]
- Zhang, Q.; Zhang, Y.; Chen, Y.; Qian, J.; Zhang, X.; Yu, K. A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases, and improves antitumor immunity in preclinical models of lung cancer. Clin. Cancer Res. 2019, 25, 3630–3642. [Google Scholar] [CrossRef] [Green Version]
- Krencz, I.; Sebestyen, A.; Fabian, K.; Mark, A.; Moldvay, J.; Khoor, A.; Kopper, L.; Papay, J. Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma. Hum. Pathol. 2017, 62, 66–73. [Google Scholar] [CrossRef]
- Puglisi, M.; Thavasu, P.; Stewart, A.; de Bono, J.S.; O’Brien, M.E.; Popat, S.; Bhosle, J.; Banerji, U. AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines. Lung Cancer 2014, 85, 141–146. [Google Scholar] [CrossRef]
- Yoshizawa, A.; Fukuoka, J.; Shimizu, S.; Shilo, K.; Franks, T.J.; Hewitt, S.M.; Fujii, T.; Cordon-Cardo, C.; Jen, J.; Travis, W.D. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin. Cancer Res. 2010, 16, 240–248. [Google Scholar] [CrossRef] [Green Version]
- Tang, Y.; Luo, J.; Zhou, Y.; Zang, H.; Yang, Y.; Liu, S.; Zheng, H.; Ma, J.; Fan, S.; Wen, Q. Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer. BMC Cancer 2022, 22, 564. [Google Scholar] [CrossRef] [PubMed]
- Shin, E.; Choi, C.M.; Kim, H.R.; Jang, S.J.; Park, Y.S. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma. Lung Cancer 2015, 89, 13–18. [Google Scholar] [CrossRef] [PubMed]
Phenotypes (Time Points) | p | |
---|---|---|
CK+PD-L1+CD45− (B) | CK+pS6+ (B) | <0.001 |
CKlowpS6+ (B) | 0.035 | |
CKlowPD-L1+CD45− (B) | CKlowpS6+ (B) | 0.011 |
CK+PD-L1+CD45− (P 1st) | CK+pS6+ (P 1st) | 0.004 |
CKlowpS6+ (P 1st) | 0.010 | |
CK+PD-L1+CD45− (EOT) | CK+pS6+ (EOT) | <0.001 |
CKlowpS6+ (EOT) | 0.039 | |
CKlowPD-L1+CD45− (EOT) | CKlowpS6+ (EOT) | 0.030 |
Characteristics | n (%) |
---|---|
Age (years) | |
Median | 67 |
Range | 43–87 |
Gender | |
Male/Female | 11 (26)/31 (74) |
Histological type | |
Adenocarcinoma | 42 (100) |
Best response | |
Complete | 1 (2) |
Partial | 12 (29) |
Stable disease | 16 (38) |
Progression disease | 13 (31) |
Last treatment cycle | |
Median | 9 |
Range | 2–58 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pantazaka, E.; Ntzifa, A.; Roumeliotou, A.; Lianidou, E.; Georgoulias, V.; Kotsakis, A.; Kallergi, G. PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC). Biomedicines 2022, 10, 1893. https://doi.org/10.3390/biomedicines10081893
Pantazaka E, Ntzifa A, Roumeliotou A, Lianidou E, Georgoulias V, Kotsakis A, Kallergi G. PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC). Biomedicines. 2022; 10(8):1893. https://doi.org/10.3390/biomedicines10081893
Chicago/Turabian StylePantazaka, Evangelia, Aliki Ntzifa, Argyro Roumeliotou, Evi Lianidou, Vassilis Georgoulias, Athanasios Kotsakis, and Galatea Kallergi. 2022. "PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)" Biomedicines 10, no. 8: 1893. https://doi.org/10.3390/biomedicines10081893